Search alternatives:
large decrease » marked decrease (Expand Search), large increases (Expand Search), large degree (Expand Search)
ct marked » _ marked (Expand Search), a marked (Expand Search), n marked (Expand Search)
b marked » _ marked (Expand Search), a marked (Expand Search), _ market (Expand Search)
a marker » _ marker (Expand Search), _ markers (Expand Search)
ai large » a large (Expand Search), i large (Expand Search), via large (Expand Search)
increase » increased (Expand Search)
large decrease » marked decrease (Expand Search), large increases (Expand Search), large degree (Expand Search)
ct marked » _ marked (Expand Search), a marked (Expand Search), n marked (Expand Search)
b marked » _ marked (Expand Search), a marked (Expand Search), _ market (Expand Search)
a marker » _ marker (Expand Search), _ markers (Expand Search)
ai large » a large (Expand Search), i large (Expand Search), via large (Expand Search)
increase » increased (Expand Search)
-
1
The proportion of ALDH+ cells progressively increases while CGA+ cells markedly decreases in <i>APC</i>-mutant colon tissues from FAP patients.
Published 2020“…<p>Representative IHC stains of normal, normal-appearing FAP, and FAP adenomatous colonic crypts are shown for the expression of the: <b>(A)</b> NEC marker chromogranin-A (CGA). <b>(B)</b> SC marker ALDH1. …”
-
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11
ALS patients’ tissues exhibit increased phosphorylation of MARK2.
Published 2021“…<p>(<b>A</b>) Representative immunoblot analyses of PKCδ, MARK2-<sup>595</sup>T, and eIF2α in the spinal cord tissues from ALS patients and non-ALS controls, indicating that increased phosphorylation of PKCδ-<sup>505</sup>T, MARK2-<sup>595</sup>T, and eIF2α-<sup>51</sup>S is a general phenotype in patient tissues. …”
-
12
Deletion of Hhp2 markedly increased Sre1 activity.
Published 2020“…<p>Deletion of <i>hhp2</i><sup>+</sup> gene markedly increased Sre1 activity in the presence/absence of CLZ (2 μg/ml to 8 μg/ml) (A), TER (2 μg/ml to 8 μg/ml) (B) or CoCl<sub>2</sub> (0.08 mM to 0.32 mM) (C). …”
-
13
-
14
Evogliptin attenuates the pyroptotic cell death of VSMCs during CER treatment by decreasing the pyroptotic-associated genes and GSDM-D cleavage efficiency <i>in-vitro.</i>
Published 2025“…<p>(A) Bar graph showed EVO significantly decreased Lactate dehydrogenase (LDH) release in CER treated P<sub>i</sub>‐induced VSMCs. …”
-
15
-
16
-
17
-
18
-
19
-
20